|Videos|January 18, 2023
The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
Author(s)Stephen J. Freedland, MD
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.
Advertisement
Advertisement
Trending on Urology Times
1
After curative-intent treatment, prostate cancer recurrence is still an unmet need
2
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
3
Rezūm outperforms combination pharmacotherapy for BPH symptoms at 1 year
4
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
5